ConcertAI

ConcertAI provides AI-driven solutions and real-world data (RWD) for the healthcare and life sciences sectors. Its offerings include predictive and generative AI software-as-a-service (SaaS) solutions aimed at enhancing clinical research and patient outcomes. The company offers a range of solutions for various needs, including specialty patient business intelligence, commercial requirements, consulting services with real-world evidence scientists, and a range of data products. ConcertAI also offers digital trial solutions (DTS), which streamline clinical trial processes through AI-based patient screening and automated enrollment.

One of its solutions is the “Clinical Trial Optimization (CTO) 2.0” platform, which offers clinical depth tools, data integration features, site and investigator-level information on previous clinical trials, and operational trial metrics. The platform also provides customizable protocols, enabling trial-runners to adjust them based on time, individual events, or clinical processes and the standard of care in different clinical settings.

In May 2024, ConcertAI announced the launch of new predictive and GenAI solutions, expansions in partnerships, and the launch of a clinical oncology suite designed to enhance research capabilities and support complex clinical study workflows. The solutions aim to provide researchers with enhanced in-depth data analysis facilities, contributing to the creation of new care strategies to improve patient outcomes. The company’s new GenAI solutions include 1) CARA AI, a comprehensive multi-modal data management platform designed to advance research across multiple fields, support collaborations, and manage multi-modal real-world data, and 2) TriaLinQ, a clinical trial screening system (as part of ConcertAI’s oncology quality management platform SmartLinQ) capable of screening 3x more patients than electronic medical records (EMR)-based screening.

In December 2023, ConcertAI acquired fellow oncology-focused patient data solutions provider CancerLinQ, expanding its capabilities in oncology data and research.

Key customers and partnerships

As of May 2024, the company worked with over 2,000 clinical providers and 45 leading biopharmaceutical companies globally. Key customers and partners include AbbVie, Bristol Myers Squibb, NeoGenomics, Caris Life Sciences, and Memorial Sloan Kettering Cancer Center.

In December 2024, ConcertAI partnered with NeoGenomics, a clinical diagnostics company, to develop CTO-H, a SaaS solution for hematological malignancies research. The solution would be deployed through ConcertAI's CARAai cloud platform, while NeoGenomics agreed to provide biomarker interpretation and specialized testing services.